Coordinating center for the NCI small cell lung cancer research consortium

摘要 该协调中心的目标包括促进调查人员之间的信息交流， NCI小细胞肺癌（SCLC）联盟，支持数据整合和数据分析，以及 作为模型系统的表征和分布的中心资源。领导这 中心由三名研究人员组成，他们对SCLC有着深入而长期的研究计划， 优势和经验互补查尔斯·鲁丁，一位经验丰富的实验室和临床 他是一位专注于SCLC的研究人员，曾指导过美国两个最大的肺癌研究项目。 在过去的13年里，他担任中心的总PI，提供行政领导， 协同约翰明娜和泰勒杰克担任该中心的共同领导人。明娜医生一直以来 几十年来，他多次领导了定义SCLC生物学的发现工作， 合作者建立了几乎所有的SCLC细胞系，作为SCLC临床前研究的基础。 research. Jacks博士在创新药物的开发和表征方面拥有丰富的经验。 在过去的几十年里， 世界各地许多活跃的研究人员正在研究小细胞肺癌的小鼠模型。我们汇集 我们认为，额外的关键调查人员和独特的资源将大大增强 中心范德比尔特的Yu Shir已经建立并指导了几个多媒体应用所使用的符合HIPAA的数据库， 调查员联盟。Nikolaus Schultz的团队开发了cBioPortal，并继续扩展和 改进了这个领先平台，用于分析和集成复杂组学级数据，支持许多多 世界各地的研究者联盟。Adi Gazdar负责UT西南大学的细胞系资源，并将 支持将这些线路分发给U 01 SCLC调查员。麻省总医院的安娜·法拉戈和杰夫·恩格尔曼， 与MSK的John Poirier和Rudin博士一起，已经建立了SCLC患者的大量资源， 衍生的异种移植物（PDX）和循环肿瘤细胞衍生的异种移植物（CDX）模型，其可用于 在联合体成员之间分配。Scott Lowe和Andrea Ventura提供了高度创新的基因 通过CRISPR/Cas9调节胚胎干细胞的工程小鼠模型，以快速评估遗传 SCLC生物学的贡献者。凯斯西方的Afshin Dowlati将提供大量的临床 注释的SCLC组织微阵列代表化学敏感性以及原发性和继发性 化学抗性疾病我们共同代表了一支卓越的团队，由三位最广泛的 在SCLC发现研究方面得到认可和认可的研究人员，在以下方面具有互补优势： 治疗翻译、基础生物学和动物模型。通过提供上述资源， 协调频繁的数据共享机会，并领导SCLC之间的年度面对面会议 研究人员，我们相信这个中心可以大大加快对这种致命疾病的进展。

ABSTRACT The goals of this Coordinating Center include facilitating information exchange among investigators in the NCI Small Cell Lung Cancer (SCLC) Consortium, supporting data integration and data analysis, and serving as a central resource for characterization and distribution of model systems. The leadership of this Center consists of a trio of investigators with deep and long-standing research programs focused on SCLC, with complementary strengths and experience. Charles Rudin, an experienced laboratory and clinical researcher focused on SCLC, who has directed two of the largest lung cancer research programs in the country over the past 13 years, serves as the overall PI of the Center, providing administrative leadership and coordination. John Minna and Tyler Jacks serve as co-leaders of the Center. Dr. Minna has consistently and repeatedly led discovery efforts defining SCLC biology over several decades, and together with his collaborators established nearly all of the SCLC cell lines that have served as the basis for SCLC preclinical research. Dr. Jacks has extensive experience in the development and characterization of innovative genetically engineered mouse models of SCLC and over the past decades has served as the primary mentor of many of the active investigators around the world working on mouse models of SCLC. We bring together additional key investigators and unqiue resources that we believe substantially add to the strengths of the Center. Yu Shir at Vanderbilt has established and directs HIPAA-compliant databases used by several multi- investigator consortia. Nikolaus Schultz’s team developed the cBioPortal and continues to expand and improve this leading platform for analysis and integration of complex –omic level data, supporting many multi- investigator consortia worldwide. Adi Gazdar oversees the cell line resource at UT Southwestern, and will support distribution of these lines to U01 SCLC investigators. Anna Farago and Jeff Engelman at MGH, together with John Poirier and Dr. Rudin at MSK, have established substantial resources of SCLC patient- derived xenografts (PDX) and circulating tumor cell-derived xenografts (CDX) models, which are available for distribution among consortium members. Scott Lowe and Andrea Ventura offer highly innovative genetically engineered mouse modeling by CRISPR/Cas9 modulation of embryonic stem cells to rapidly assess genetic contributors to SCLC biology. Afshin Dowlati at Case Western will contribute a large collection of clinically annotated SCLC tissue microarrays representing chemosensitive as well as primary and secondary chemoresistant disease. Together we represent an exceptional team, led by three of the most widely recognized and established investigators in SCLC discovery research, with complementary strengths in therapeutic translation, basic biology, and animal modeling. By providing the resources above, and by coordinating frequent data-sharing opportunities and leading annual face-to-face meetings among SCLC investigators, we believe this Center can substantially accellerate progress against this deadly disease.